Clinical Trials Logo

Clinical Trial Summary

Assessment of effectiveness, safety and local immune activation of Oncolytic Viruses H101 in patients with refractory malignant ascites.


Clinical Trial Description

This study is to evaluate the effectiveness of local immune activation, and safety in patients with refractory malignant ascites after Intraperitoneal injection of oncolytic Viruses H101. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04771676
Study type Interventional
Source Fudan University
Contact
Status Completed
Phase Phase 2
Start date March 5, 2021
Completion date January 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT01852409 - Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites Phase 1
Withdrawn NCT02477657 - Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology
Completed NCT02891369 - Analysis of Patients Treated With Bevacizumab Intraperitoneal for the Treatment of Refractory Malignant Ascites
Recruiting NCT05303844 - Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites Phase 1